NEWEarnings
Connect Biopharma Stock Rated Buy at $7 by H.C. Wainwright
Published on 6/25/2026

AI Summary
H.C. Wainwright has reiterated a Buy rating on Connect Biopharma (CNTB) stock, setting a price target of $7. This recommendation indicates confidence in the company's future performance and may influence investor sentiment. The current trading price suggests potential upside for investors based on the analyst's target. An affirmation from notable analysts can impact liquidity and trading volume as stakeholders evaluate their strategies.
Related News

Earnings
Micron (MU) Shares Surge 18% After Strong Earnings Report
Jun 25

Earnings
Darden Restaurants (DRI) Reports Q4 Earnings, EPS at $3.66 Beats Estimates
Jun 25

Earnings
argenx (ARGX) Stock Rating Reiterated Amid Myositis Trial Update
Jun 25

Earnings
Ionis (IONS) Stock Price Target Raised to $130 Following FDA Approval
Jun 25